Last reviewed · How we verify
Conbercept ophthalmic injection
Conbercept ophthalmic injection is a VEGF/PlGF inhibitor; recombinant fusion protein Small molecule drug developed by Chengdu Kanghong Biotech Co., Ltd.. It is currently in Phase 3 development for Neovascular age-related macular degeneration (wet AMD), Diabetic macular edema (DME), Retinal vein occlusion (RVO). Also known as: KH902.
Conbercept is a recombinant fusion protein that binds and neutralizes vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) to inhibit pathological neovascularization in the eye.
Conbercept ophthalmic injection is a vascular endothelial growth factor A inhibitor used to treat various eye conditions, including macular edema, central retinal vein occlusion, polypoid choroidal vasculopathy, choroid neovascularization secondary to degenerative myopia, and retinal vein occlusion. It is administered via intravitreal injection in the form of a 0.5mg dose.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Conbercept ophthalmic injection |
|---|---|
| Also known as | KH902 |
| Sponsor | Chengdu Kanghong Biotech Co., Ltd. |
| Drug class | VEGF/PlGF inhibitor; recombinant fusion protein |
| Target | VEGF (vascular endothelial growth factor); PlGF (placental growth factor) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
Conbercept functions as a VEGF/PlGF trap by combining the extracellular domains of VEGF receptors 1 and 2 fused to the Fc region of human immunoglobulin G1. This construct has higher binding affinity for VEGF and PlGF compared to bevacizumab and ranibizumab, allowing it to more effectively suppress abnormal blood vessel growth and vascular permeability in retinal diseases. By blocking these pro-angiogenic pathways, it reduces vision loss and retinal edema associated with age-related macular degeneration and diabetic retinopathy.
Approved indications
- Neovascular age-related macular degeneration (wet AMD)
- Diabetic macular edema (DME)
- Retinal vein occlusion (RVO)
Common side effects
- Conjunctival hemorrhage
- Eye pain
- Floaters
- Intraocular pressure elevation
- Endophthalmitis
Key clinical trials
- Biological Changes in Fibrovascular Membranes of Patients With Proliferative Diabetic Retinopathy Following Faricimab Injection (NA)
- Aqueous Humor Proteome in Retinal Vein Occlusion With Macular Edema
- Efficacy and Safety of Low-dose Conbercept for Retinopathy of Prematurity Therapy (NA)
- Evaluation of RC28-E Injection in Diabetic Macular Edema (PHASE2)
- Real World Study of the Effectiveness and Safety of Conbercept Ophthalmic Injection in the Treatment of Retinopathy of Prematurity - Multicenter, Retrospective and Observational Study Based on Real World Data
- Conbercept Ophthalmic Injection for Patients With Macular Edema Caused by Branch Retinal Vein Occlusion (PHASE3)
- Conbercept Ophthalmic Injection for Patients of Central Retinal Vein Occlusion (PHASE3)
- A Clinical Study on the Efficacy and Safety of VEC Intravenous Chemotherapy Combined With Conbercept Intravitreal Injection in the Treatment of Retinoblastoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Conbercept ophthalmic injection CI brief — competitive landscape report
- Conbercept ophthalmic injection updates RSS · CI watch RSS
- Chengdu Kanghong Biotech Co., Ltd. portfolio CI
Frequently asked questions about Conbercept ophthalmic injection
What is Conbercept ophthalmic injection?
How does Conbercept ophthalmic injection work?
What is Conbercept ophthalmic injection used for?
Who makes Conbercept ophthalmic injection?
Is Conbercept ophthalmic injection also known as anything else?
What drug class is Conbercept ophthalmic injection in?
What development phase is Conbercept ophthalmic injection in?
What are the side effects of Conbercept ophthalmic injection?
What does Conbercept ophthalmic injection target?
Related
- Drug class: All VEGF/PlGF inhibitor; recombinant fusion protein drugs
- Target: All drugs targeting VEGF (vascular endothelial growth factor); PlGF (placental growth factor)
- Manufacturer: Chengdu Kanghong Biotech Co., Ltd. — full pipeline
- Therapeutic area: All drugs in Ophthalmology
- Indication: Drugs for Neovascular age-related macular degeneration (wet AMD)
- Indication: Drugs for Diabetic macular edema (DME)
- Indication: Drugs for Retinal vein occlusion (RVO)
- Also known as: KH902
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing